{"id":"W4410840498","doi":"10.1016/j.esmoop.2025.105065","title":"Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Eli Lilly Japan; Chugai Pharmaceutical; Genentech; Eisai Canada; Otsuka Pharmaceutical; Merck Sharp and Dohme; Ono Pharmaceutical; Eisai; Sanofi; Exelixis; Moderna; F. Hoffmann-La Roche; Taiho Pharmaceutical; Boston Scientific Corporation; Ipsen; BeiGene; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Lenvatinib; Pembrolizumab; Hepatocellular carcinoma; Medicine; Oncology; Internal medicine; Cancer; Sorafenib; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008041072,0.0003693956,0.002389891,0.000357982,0.0002049133,0.00001462648,0.0005196209,0.0001496922,0.0001967791],"category_scores_gemma":[0.0005021525,0.0002642652,0.0007505679,0.001778771,0.0001292509,0.00009034455,0.0002533539,0.0001370812,0.000002528156],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003491411,"about_ca_system_score_gemma":0.001063524,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03881303,"about_ca_topic_score_gemma":0.005758283,"domain_scores_codex":[0.9963112,0.0004263736,0.001874061,0.0005787848,0.0004612241,0.000348314],"domain_scores_gemma":[0.9963054,0.0007481985,0.001148559,0.001278747,0.0003673948,0.0001517125],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01257311,0.003325053,0.9681166,0.0004185583,0.007720628,0.000006642691,0.003408306,0.0002281848,0.0001224837,0.0005026483,0.00008832232,0.003489419],"study_design_scores_gemma":[0.09441754,0.01537209,0.8477042,0.0003225995,0.009570639,0.000001230787,0.003522082,0.01154784,0.01621464,0.00009787672,0.0008499275,0.0003793162],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9881898,0.001017101,0.00003805294,0.001645885,0.0001761111,0.007284366,0.0001765462,0.00002182846,0.001450357],"genre_scores_gemma":[0.9972562,0.0000798497,0.0002407963,0.0000823539,0.0000150955,0.000567427,0.0002961099,0.00003112133,0.00143107],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1204124,"threshold_uncertainty_score":0.9999809,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1833503997129842,"score_gpt":0.37988705921614,"score_spread":0.1965366595031558,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}